In the month of June alone, the FDA demonstrated its most extreme regulatory capture to date with its Vaccine and Related Biological Products Advisory Committee's (VRBPAC) approval for (1) Emergency Use Authorization (EUA) to vaccinate the final age cohort of six-month-old babies to five-year-old toddlers (6/14-15/22); and (2) Emergency Use Authorization (EUA) to reformulate Pfizer and Moderna original vaccines to accommodate current and future variants without clinical trials (6/28/22).
